CN108291261A - 用于预测对抗tnf治疗的响应的方法 - Google Patents

用于预测对抗tnf治疗的响应的方法 Download PDF

Info

Publication number
CN108291261A
CN108291261A CN201680071029.6A CN201680071029A CN108291261A CN 108291261 A CN108291261 A CN 108291261A CN 201680071029 A CN201680071029 A CN 201680071029A CN 108291261 A CN108291261 A CN 108291261A
Authority
CN
China
Prior art keywords
target molecule
tnf
expression
sample
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680071029.6A
Other languages
English (en)
Chinese (zh)
Inventor
海伦·路易丝·赖特
罗伯特·约翰·穆特
史蒂文·威廉·爱德华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Liverpool
Original Assignee
University of Liverpool
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Liverpool filed Critical University of Liverpool
Publication of CN108291261A publication Critical patent/CN108291261A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Theoretical Computer Science (AREA)
  • Signal Processing (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201680071029.6A 2015-12-03 2016-12-02 用于预测对抗tnf治疗的响应的方法 Pending CN108291261A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1521357.2 2015-12-03
GBGB1521357.2A GB201521357D0 (en) 2015-12-03 2015-12-03 Methods for predicting response to anti-TNF therapy
PCT/GB2016/053798 WO2017093750A1 (en) 2015-12-03 2016-12-02 Methods for predicting response to anti-tnf therapy

Publications (1)

Publication Number Publication Date
CN108291261A true CN108291261A (zh) 2018-07-17

Family

ID=55234362

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680071029.6A Pending CN108291261A (zh) 2015-12-03 2016-12-02 用于预测对抗tnf治疗的响应的方法

Country Status (8)

Country Link
US (1) US20190367984A1 (enExample)
EP (1) EP3384044A1 (enExample)
JP (1) JP2018537100A (enExample)
CN (1) CN108291261A (enExample)
AU (1) AU2016364003A1 (enExample)
CA (1) CA3005695A1 (enExample)
GB (1) GB201521357D0 (enExample)
WO (1) WO2017093750A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729401A (zh) * 2019-10-04 2022-07-08 密歇根大学董事会 确定银屑病治疗中对抗肿瘤坏死因子疗法的应答性的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018113694A (ru) 2015-09-17 2019-10-17 Эмджен Инк. Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23
EP3654993A4 (en) * 2017-07-17 2021-08-25 The Broad Institute, Inc. CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
CN108047327B (zh) * 2017-11-29 2020-08-07 中国医学科学院北京协和医院 一种检测骨关节炎的生物标志物及其应用
WO2019159186A1 (en) * 2018-02-19 2019-08-22 Genefron Ltd. Methods of determining response to tnf alpha blockers
EP3765634A4 (en) 2018-03-16 2021-12-01 Scipher Medicine Corporation METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES
SG11202104882WA (en) * 2018-11-15 2021-06-29 Ampel Biosolutions Llc Machine learning disease prediction and treatment prioritization
JP2022541125A (ja) 2019-06-27 2022-09-22 サイファー メディシン コーポレーション 患者を層別化するための分類子の開発
CA3199737A1 (en) * 2020-11-30 2022-06-02 Tobin Dickerson Microneedle devices and methods, and skin condition assays
US20220291238A1 (en) * 2021-03-12 2022-09-15 Janssen Biotech, Inc. Methods for Predicting Treatment Response in Ulcerative Colitis
CN113373218A (zh) * 2021-08-04 2021-09-10 杭州浙大迪迅生物基因工程有限公司 一组检测人嗜酸性粒细胞阳离子蛋白mRNA表达的引物组和试剂盒
CN116559453A (zh) * 2022-11-22 2023-08-08 杭州广科安德生物科技有限公司 一种用于肺癌检测的生物标志物
WO2026047197A1 (en) * 2024-08-30 2026-03-05 Sanofi Biotechnology Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154423A2 (en) * 2007-06-08 2008-12-18 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2012153187A2 (en) * 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
WO2014060785A2 (en) * 2012-10-19 2014-04-24 Egis Pharmaceuticals Public Limited Company DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR
US20140135225A1 (en) * 2012-11-15 2014-05-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Spe Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658171A1 (en) * 2006-07-13 2008-01-17 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2008132176A2 (en) * 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
EP2192197A1 (en) * 2008-11-27 2010-06-02 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist
CN102597268B (zh) * 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154423A2 (en) * 2007-06-08 2008-12-18 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2012153187A2 (en) * 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
WO2014060785A2 (en) * 2012-10-19 2014-04-24 Egis Pharmaceuticals Public Limited Company DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR
US20140135225A1 (en) * 2012-11-15 2014-05-15 New York Society For The Ruptured And Crippled Maintaining The Hospital For Spe Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIRK KOCZAN等: ""Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept"", 《ARTHRITIS RESEARCH & THERAPY》 *
PETER C. GRAYSON等: ""Neutrophil-Related Gene Expression And Low-Density Granulocytes Associated with Disease Activity and Response to Treatment in ANCA-Associated Vasculitis"", 《ARTHRITIS RHEUMATOL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729401A (zh) * 2019-10-04 2022-07-08 密歇根大学董事会 确定银屑病治疗中对抗肿瘤坏死因子疗法的应答性的方法

Also Published As

Publication number Publication date
GB201521357D0 (en) 2016-01-20
WO2017093750A1 (en) 2017-06-08
JP2018537100A (ja) 2018-12-20
US20190367984A1 (en) 2019-12-05
AU2016364003A1 (en) 2018-06-28
CA3005695A1 (en) 2017-06-08
EP3384044A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
CN108291261A (zh) 用于预测对抗tnf治疗的响应的方法
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
JP7082945B2 (ja) Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
CA2889087C (en) Diagnostic method for predicting response to tnf.alpha. inhibitor
US10036075B2 (en) Risk stratification in influenza
Xia et al. Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment
US20130095099A1 (en) Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd)
US20250273295A1 (en) Detecting the presence of a tumor based on methylation status of cell-free nucleic acid molecules
EP2668287B1 (en) Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody
US20220351806A1 (en) Biomarker Panels for Guiding Dysregulated Host Response Therapy
AU2022233979A9 (en) Methods for predicting treatment response in ulcerative colitis
EP3983565B1 (en) Method of stratifying subjects into sub-groups for therapeutic treatment
US20220290243A1 (en) Identification of patients that will respond to chemotherapy
EP3146072B1 (en) Circulating mirnas as biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-tnfalpha
WO2014072086A1 (en) Biomarkers for prognosis of lung cancer
Zaripova et al. Genes, antibodies, and cytokines in systemic lupus erythematosus: Update of potential biomarkers
Çitli et al. An Alternative Perspective to the FMF Clinic: MCP-1 (A-2518G) and CCR2 (G190A) Polymorphisms and MCP1 Expression
Koturan Pathogenic mechanism of chronic inflammatory diseases: linking genotype, immune cell function and pathology in Spondyloarthritis
WO2022212890A1 (en) Companion diagnostic and therapies for dysregulated host response
JP2018518198A (ja) リンパ性血液疾患の予後診断方法
WO2026047608A1 (en) Methods related to multiple myeloma and precursors thereof
Meskó Peripheral Blood Gene Expression Profiling as a Tool in Exploring the Pharmacogenomics of Autoimmune Diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180717

WD01 Invention patent application deemed withdrawn after publication